ST Pharm Co.,Ltd.

KOSDAQ:A237690 Stok Raporu

Piyasa değeri: ₩2.3t

ST PharmLtd Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Mooje Sung

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresi2.1yrs
CEO sahipliğin/a
Yönetim ortalama görev süresi2.6yrs
Yönetim Kurulu ortalama görev süresiVeri yok

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Jul 10

Should You Be Adding ST PharmLtd (KOSDAQ:237690) To Your Watchlist Today?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analiz Makalesi • Mar 27

ST PharmLtd's (KOSDAQ:237690) Earnings Are Of Questionable Quality

ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) announced strong profits, but the stock was stagnant. Our analysis suggests that...
Analiz Makalesi • Feb 02

ST Pharm Co.,Ltd. (KOSDAQ:237690) Stocks Shoot Up 39% But Its P/S Still Looks Reasonable

ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) shares have continued their recent momentum with a 39% gain in the last month...
Analiz Makalesi • Jan 24

ST PharmLtd (KOSDAQ:237690) Seems To Use Debt Quite Sensibly

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analiz Makalesi • Dec 30

Is There An Opportunity With ST Pharm Co.,Ltd.'s (KOSDAQ:237690) 22% Undervaluation?

Key Insights The projected fair value for ST PharmLtd is ₩152,430 based on 2 Stage Free Cash Flow to Equity ST PharmLtd...
Analiz Makalesi • Dec 15

Earnings Tell The Story For ST Pharm Co.,Ltd. (KOSDAQ:237690) As Its Stock Soars 27%

ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) shares have continued their recent momentum with a 27% gain in the last month...
Analiz Makalesi • Oct 29

ST Pharm Co.,Ltd.'s (KOSDAQ:237690) Share Price Matching Investor Opinion

When close to half the companies in Korea have price-to-earnings ratios (or "P/E's") below 14x, you may consider ST...
Analiz Makalesi • Sep 11

A Look At The Fair Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)

Key Insights ST PharmLtd's estimated fair value is ₩81,102 based on 2 Stage Free Cash Flow to Equity With ₩93,700 share...
Analiz Makalesi • Aug 26

Is ST PharmLtd (KOSDAQ:237690) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analiz Makalesi • Aug 05

Here's Why ST PharmLtd (KOSDAQ:237690) Has Caught The Eye Of Investors

KOSDAQ:A237690 1 Year Share Price vs Fair Value Explore ST PharmLtd's Fair Values from the Community and select yours...
Analiz Makalesi • Jun 13

Shareholders Should Be Pleased With ST Pharm Co.,Ltd.'s (KOSDAQ:237690) Price

ST Pharm Co.,Ltd.'s ( KOSDAQ:237690 ) price-to-earnings (or "P/E") ratio of 55.4x might make it look like a strong sell...
Analiz Makalesi • May 26

ST PharmLtd (KOSDAQ:237690) Takes On Some Risk With Its Use Of Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analiz Makalesi • May 07

Calculating The Intrinsic Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)

Key Insights ST PharmLtd's estimated fair value is ₩66,531 based on 2 Stage Free Cash Flow to Equity Current share...
Analiz Makalesi • Apr 02

ST PharmLtd's (KOSDAQ:237690) Earnings Are Built On Soft Foundations

Solid profit numbers didn't seem to be enough to please ST Pharm Co.,Ltd.'s ( KOSDAQ:237690 ) shareholders. Our...
Analiz Makalesi • Feb 11

Getting In Cheap On ST Pharm Co.,Ltd. (KOSDAQ:237690) Might Be Difficult

With a price-to-earnings (or "P/E") ratio of 58.1x ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) may be sending very bearish...
Analiz Makalesi • Jan 21

Does ST PharmLtd (KOSDAQ:237690) Have A Healthy Balance Sheet?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analiz Makalesi • Nov 22

Should You Be Adding ST PharmLtd (KOSDAQ:237690) To Your Watchlist Today?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analiz Makalesi • Aug 30

ST Pharm Co.,Ltd.'s (KOSDAQ:237690) Shares Climb 29% But Its Business Is Yet to Catch Up

The ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) share price has done very well over the last month, posting an excellent gain...
Analiz Makalesi • Aug 17

Is Now The Time To Put ST PharmLtd (KOSDAQ:237690) On Your Watchlist?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Analiz Makalesi • May 09

Is ST Pharm Co.,Ltd. (KOSDAQ:237690) Trading At A 41% Discount?

Key Insights ST PharmLtd's estimated fair value is ₩157,784 based on 2 Stage Free Cash Flow to Equity Current share...
Analiz Makalesi • Mar 22

Why ST PharmLtd's (KOSDAQ:237690) Earnings Are Better Than They Seem

ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) announced a healthy earnings result recently, and the market rewarded it with a...
Analiz Makalesi • Mar 18

ST Pharm Co.,Ltd. (KOSDAQ:237690) Stock Rockets 54% As Investors Are Less Pessimistic Than Expected

The ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) share price has done very well over the last month, posting an excellent gain...
Analiz Makalesi • Mar 16

Investors Who Bought ST PharmLtd (KOSDAQ:237690) Shares A Year Ago Are Now Up 221%

It hasn't been the best quarter for ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) shareholders, since the share price has fallen...
Analiz Makalesi • Jan 22

Calculating The Fair Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)

Today we will run through one way of estimating the intrinsic value of ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) by taking...
Analiz Makalesi • Dec 23

What Type Of Shareholders Own The Most Number of ST Pharm Co.,Ltd. (KOSDAQ:237690) Shares?

A look at the shareholders of ST Pharm Co.,Ltd. ( KOSDAQ:237690 ) can tell us which group is most powerful...
Analiz Makalesi • Nov 26

Health Check: How Prudently Does ST PharmLtd (KOSDAQ:237690) Use Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

CEO

Mooje Sung

2.1yrs
Görev süresi

Mooje Sung is Chief Executive Officer of ST Pharm Co. Ltd. from July 2024. Mooje Sung has Ph.D. in Organic Chemistry from University Of Alabama, M.S. in Organic Chemistry from Sogang University and has B.S...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Mooje Sung
Chief Executive Officer2.1yrsVeri yokVeri yok
Yonghoon Choi
CFO & VPless than a yearVeri yok0.0017%
₩ 38.9m
Dong-Ryul Lee
Head of Management Support Division & Inside Directorno dataVeri yokVeri yok
Seokwoo Choi
Head of Business Development & Senior VPno dataVeri yok0.038%
₩ 868.9m
Jun Young Choi
Head of R&D Center and Senior VP5.7yrsVeri yokVeri yok
Sunki Chang
Senior Vice President3.6yrsVeri yokVeri yok
JungYuel Yun
Head of Quality Division & VP2.6yrsVeri yokVeri yok
JinSeok Lim
Head of Development & Manufacturing and VP2.6yrsVeri yokVeri yok
2.6yrs
Ortalama Görev Süresi
58yo
Ortalama Yaş

Deneyimli Yönetim: A237690 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.6 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/08/21 11:17
Gün Sonu Hisse Fiyatı2026/08/21 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

ST Pharm Co.,Ltd. 12 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Jisoo LeeDAOL Investment & Securities Co., Ltd.
Myung Sun LeeDB Financial Investment Co. Ltd.
Haesoon KwonEugene Investment & Securities Co Ltd.